All News

The concept of angel investing - in which individuals devote both their time and money to nurturing young companies - has evolved over the past decade from an unknown or poorly understand phenomena in many parts of Europe to an established form of finance.

Spanish researchers have developed a technology that allows even the tone deaf to pick music with the right rhythm and tempo to keep the mass swaying.

Venture capital firms used to moan that business angels were unprofessional and hard to work with. But Europe's new breed of angel investor networks appears anything but that, says Mary Lisbeth D'Amico

The annual growth of biotech cultivation grew last year at its slowest pace since 1996, when biotech crops were first commercialised, according to a report by the International Service for the Acquisition of Agri-Biotech Applications, a non-profit group that advocates the use of bio-crops.

Marc Van Montagu, Europe's founding father of genetically modified crops and a powerful advocate for their acceptance in Europe, speaks to Science|Business News Editor Thomas Lau.

Researchers at the Advanced Technology Institute at the University of Surrey recently reported that they have shown and observed a phenomenon called negative differential resistance - holding out the prospect of a new generation of cheap and fast semiconductors.

Venture capitalists are once again funding nanotech start-ups, but their overall investment is small compared with government funding and corporate R&D spending, says to a new report.

In his first interview since taking up the job, Bruno van Pottelsberghe, the 37-year-old newly appointed chief economist at the European Patent Office, bemoans the failure to create a single EU-wide patent.

The UK's stem cell community has reacted with collective dismay at the final confirmation that Hwang Woo-suk's claims to have generated patient-specific embryonic stem cell lines were fraudulent. Nuala Moran takes a look.

Micromet AG, a spin-off from the Institute for Immunology at Munich University, said it has agreed to grant four licenses of its single chain antibody technology to Abbott Laboratories, Alligator Bioscience AB, Haptogen Ltd. and an unnamed biopharmaceutical company, for the development of cancer treatments.

Lipoxen Plc, a drug spin-out company from the University of London's School of Pharmacy, said it has raised £3.78 million from a placing of 28 million shares for hiring news staff for preclinical trials to treat diabetes, Pneumococcal infections, and hepatitis C.